Data

N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial

Western Sydney University
Sarris, Jerome ; Byrne, Gerard J ; Castle, David ; Bousman, Chad ; Oliver, Georgina ; Cribb, Lachlan ; Blair-West, Scott ; Brakoulias, Vlasios ; Camfield, David ; Ee, Carolyn ; Chamoli, Suneel ; Boschen, Mark ; Dean, Olivia M ; Dowling , Nathan ; Menon, Ranjit ; Murphy, Jenifer ; Metri, Joelle ; Nguyen, Thomas P ; Wong, Andrew ; Jordan, Rebecca ; Karamacoska, Diana ; Rossell, Susan L ; Berk, Michael ; Ng, Chee H
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.26183/45ay-r974&rft.title=N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial&rft.identifier=10.26183/45ay-r974&rft.publisher=Western Sydney University&rft.description=This study seeks to elucidate the benefits of NAC augmentation (2-4 grams/day) compared to placebo in the treatment of OCD, in a 24-week, multi-centre, randomized, double-blind, placebo controlled trial. It is hypothesized that NAC will be superior over placebo for improving OCD symptoms as measured by a reduction in Y-BOCS scores from baseline against each subsequent time point (W4, W8, W12, W16, W20 and W24). Additional benefits are anticipated for relieving anxiety as well as improving mood, functioning and overall quality of life. The dataset relates to the clinical trial ACTRN12616000847415 N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial. This data cannot be shared publicly due to ethics approval conditions. To discuss this data, please contact the NICM Health Research Institute nicm@westernsydney.edu.au.&rft.creator=Sarris, Jerome &rft.creator=Byrne, Gerard J &rft.creator=Castle, David &rft.creator=Bousman, Chad &rft.creator=Oliver, Georgina &rft.creator=Cribb, Lachlan &rft.creator=Blair-West, Scott &rft.creator=Brakoulias, Vlasios &rft.creator=Camfield, David &rft.creator=Ee, Carolyn &rft.creator=Chamoli, Suneel &rft.creator=Boschen, Mark &rft.creator=Dean, Olivia M &rft.creator=Dowling , Nathan &rft.creator=Menon, Ranjit &rft.creator=Murphy, Jenifer &rft.creator=Metri, Joelle &rft.creator=Nguyen, Thomas P &rft.creator=Wong, Andrew &rft.creator=Jordan, Rebecca &rft.creator=Karamacoska, Diana &rft.creator=Rossell, Susan L &rft.creator=Berk, Michael &rft.creator=Ng, Chee H &rft.date=2025&rft.relation=http://doi.org/10.1016/j.pnpbp.2022.110550&rft.coverage=Australia&rft_rights=Copyright Western Sydney University&rft_subject=Anxiety&rft_subject=Clinical trial&rft_subject=Nutraceutical&rft_subject=Obsessive compulsive disorder&rft_subject=Oxidative stress&rft_subject=ACTRN12616000847415&rft_subject=Traditional, complementary and integrative medicine not elsewhere classified&rft_subject=Traditional, complementary and integrative medicine&rft_subject=HEALTH SCIENCES&rft_subject=Other health sciences not elsewhere classified&rft_subject=Other health sciences&rft_subject=Mental health&rft_subject=Public health (excl. specific population health)&rft_subject=HEALTH&rft_subject=Nutrition&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Licence & Rights:

view details

Copyright Western Sydney University

Access:

Restrictions apply view details

Restricted

Full description

This study seeks to elucidate the benefits of NAC augmentation (2-4 grams/day) compared to placebo in the treatment of OCD, in a 24-week, multi-centre, randomized, double-blind, placebo controlled trial. It is hypothesized that NAC will be superior over placebo for improving OCD symptoms as measured by a reduction in Y-BOCS scores from baseline against each subsequent time point (W4, W8, W12, W16, W20 and W24). Additional benefits are anticipated for relieving anxiety as well as improving mood, functioning and overall quality of life.

The dataset relates to the clinical trial ACTRN12616000847415 N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial. This data cannot be shared publicly due to ethics approval conditions.

To discuss this data, please contact the NICM Health Research Institute nicm@westernsydney.edu.au.

Created: 2025-04-01

Data time period: 15 11 2017 to 30 06 2020

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related People

Spatial Coverage And Location

text: Australia

Subjects
ACTRN12616000847415 | Anxiety | Clinical trial | Health | Health Sciences | Mental Health | Nutraceutical | Nutrition | Obsessive compulsive disorder | Other Health Sciences | Other Health Sciences Not Elsewhere Classified | Oxidative stress | Public Health (Excl. Specific Population Health) | Traditional, Complementary and Integrative Medicine | Traditional, Complementary and Integrative Medicine Not Elsewhere Classified |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers
  • DOI : 10.26183/45AY-R974
  • Local : research-data.westernsydney.edu.au/published/d1ed32a0a61211efbb9db34536804e8c
Similar data you may be interested in: